Quizartinib

Results: 9



#Item
1Day by Day Program Sunday 25th March 2:00- 6:00pm Conference Registration Desk Opens (Wandiny Room)

Day by Day Program Sunday 25th March 2:00- 6:00pm Conference Registration Desk Opens (Wandiny Room)

Add to Reading List

Source URL: www.sapro.com.au

Language: English - Date: 2012-03-15 17:19:40
2FLT3 Ligand Fms-like Tyrosine Kinase 3 Ligand human, recombinant, E. coli Cat. No.

FLT3 Ligand Fms-like Tyrosine Kinase 3 Ligand human, recombinant, E. coli Cat. No.

Add to Reading List

Source URL: www.jenabioscience.com

Language: English - Date: 2014-04-14 06:01:17
3   AMBIT BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP TO RESEARCH, DEVELOP AND COMMERCIALIZE FLT3 KINASE INHIBITORS IN MULTIPLE INDICATIONS Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million

  AMBIT BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP TO RESEARCH, DEVELOP AND COMMERCIALIZE FLT3 KINASE INHIBITORS IN MULTIPLE INDICATIONS Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2009-12-17 23:42:07
4Microsoft Word - ASH 2012 Announcement Press Release - final

Microsoft Word - ASH 2012 Announcement Press Release - final

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2012-11-06 04:03:33
5Microsoft Word - ASH 2012 Announcement Press Release (final)

Microsoft Word - ASH 2012 Announcement Press Release (final)

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2012-12-10 18:40:36
6    AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA    Potential to Support U.S. Regulatory Filing   

    AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA    Potential to Support U.S. Regulatory Filing   

Add to Reading List

Source URL: www.forwardventures.com

Language: English - Date: 2011-08-15 11:58:25
7Microsoft Word[removed]Partnership with Ambit.doc

Microsoft Word[removed]Partnership with Ambit.doc

Add to Reading List

Source URL: www.forwardventures.com

Language: English - Date: 2011-08-15 11:58:25
8Microsoft Word - ASH2009 Phase I study results - FINAL.doc

Microsoft Word - ASH2009 Phase I study results - FINAL.doc

Add to Reading List

Source URL: www.forwardventures.com

Language: English - Date: 2011-08-15 11:58:25
9CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1

CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1

Add to Reading List

Source URL: www.gistsupport.org

Language: English - Date: 2013-01-20 11:10:44